These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
506 related articles for article (PubMed ID: 20183526)
1. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. Neafsey P; Ginsberg G; Hattis D; Sonawane B J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526 [TBL] [Abstract][Full Text] [Related]
2. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134 [TBL] [Abstract][Full Text] [Related]
5. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy]. Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 CYP2D6. Wolf CR; Smith G IARC Sci Publ; 1999; (148):209-29. PubMed ID: 10493260 [TBL] [Abstract][Full Text] [Related]
7. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Buzková H; Pechandová K; Slanar O; Perlík F Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358 [TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. Walker K; Ginsberg G; Hattis D; Johns DO; Guyton KZ; Sonawane B J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):440-72. PubMed ID: 20183529 [TBL] [Abstract][Full Text] [Related]
10. Genetic Polymorphism in Glutathione Transferases (GST): Population distribution of GSTM1, T1, and P1 conjugating activity. Ginsberg G; Smolenski S; Hattis D; Guyton KZ; Johns DO; Sonawane B J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):389-439. PubMed ID: 20183528 [TBL] [Abstract][Full Text] [Related]
11. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570 [TBL] [Abstract][Full Text] [Related]
12. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645 [TBL] [Abstract][Full Text] [Related]
13. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Zhou SF Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501 [TBL] [Abstract][Full Text] [Related]
15. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883 [TBL] [Abstract][Full Text] [Related]
16. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321 [TBL] [Abstract][Full Text] [Related]
17. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Zhou SF; Liu JP; Chowbay B Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967 [TBL] [Abstract][Full Text] [Related]
18. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325 [TBL] [Abstract][Full Text] [Related]